Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

NCT01258062 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine

Interventions

DRUG: GelVac™ nasal powder H5N1 influenza vaccine.
DRUG: Placebo

Sponsor

Alachua Government Services, Inc.